Advances at the Interface of Cancer and Systemic Sclerosis.
autoantibodies
cancer
malignancy
scleroderma
systemic sclerosis
Journal
Journal of scleroderma and related disorders
ISSN: 2397-1983
Titre abrégé: J Scleroderma Relat Disord
Pays: England
ID NLM: 101685427
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
ppublish
Résumé
The interface between systemic sclerosis (SSc) and cancer has offered valuable insights into our understanding of SSc disease pathogenesis. Defining SSc subgroups both temporally and serologically has been instrumental in stratifying cancer risk, with autoantibodies to RNA polymerase 3 (RNApol3), RNA polymerase I large subunit (RPA194), RNA Binding Region Containing 3 (RNPC3), and centromere identifying subgroups at increased or decreased risk of cancer. Clinically, improved subgrouping of SSc patients provides the opportunity to detect cancer at earlier stages of disease while increasing our efficiency of cancer assessment. Additional studies are needed to define the optimal approach to cancer screening in SSc, and validation studies in different cohorts will be needed to confirm all findings.
Identifiants
pubmed: 34124375
doi: 10.1177/2397198320905983
pmc: PMC8188901
mid: NIHMS1577787
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50-57Subventions
Organisme : NIAMS NIH HHS
ID : K23 AR075898
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR070254
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073208
Pays : United States
Références
J Rheumatol. 2017 May;44(5):639-647
pubmed: 28089973
Arthritis Rheum. 2013 Jul;65(7):1913-21
pubmed: 23576072
Cancer. 1995 Sep 1;76(5):910-4
pubmed: 8625197
J Clin Invest. 1987 Jan;79(1):65-72
pubmed: 2432091
Br J Dermatol. 2010 Oct;163(4):800-6
pubmed: 20854403
Arthritis Rheum. 2010 Sep;62(9):2787-95
pubmed: 20506513
Intern Med. 2012;51(13):1683-8
pubmed: 22790126
Ann Rheum Dis. 2018 Aug;77(8):1179-1186
pubmed: 29678941
Rheumatology (Oxford). 2015 Nov;54(11):1991-9
pubmed: 26106211
Arthritis Rheum. 1993 Apr;36(4):460-4
pubmed: 8457221
Arthritis Rheumatol. 2015 Feb;67(2):317-26
pubmed: 25371098
Autoimmun Rev. 2017 May;16(5):461-468
pubmed: 28285170
Arthritis Res Ther. 2014 Feb 14;16(1):R53
pubmed: 24524733
Ann Rheum Dis. 1993 Jul;52(7):531-3
pubmed: 8346981
Science. 2014 Jan 10;343(6167):152-7
pubmed: 24310608
Scand J Rheumatol. 2009;38(4):299-303
pubmed: 19308805
Arthritis Rheumatol. 2017 Jun;69(6):1306-1312
pubmed: 28217959
Neoplasma. 2005;52(1):32-5
pubmed: 15739023
BJU Int. 2017 Dec;120(6):793-798
pubmed: 28058757
Arthritis Rheum. 1985 Dec;28(12):1336-40
pubmed: 4084328
Rheumatol Int. 2011 May;31(5):641-5
pubmed: 20058012
J Rheumatol. 2006 Jun;33(6):1113-6
pubmed: 16622904
J Rheumatol. 2011 Jul;38(7):1329-34
pubmed: 21459934
Scand J Rheumatol. 2012 Feb;41(1):44-9
pubmed: 22150162
Ann Rheum Dis. 2007 Apr;66(4):551-3
pubmed: 16984943
Autoimmun Rev. 2011 Feb;10(4):194-200
pubmed: 20933614
Clin Rheumatol. 2000;19(2):123-6
pubmed: 10791623
Arthritis Rheumatol. 2019 Sep;71(9):1571-1579
pubmed: 30888702
Ann Rheum Dis. 2003 Aug;62(8):728-31
pubmed: 12860727
Rheumatology (Oxford). 2013 Jan;52(1):143-54
pubmed: 23175568
J Rheumatol. 2003 Sep;30(9):1994-6
pubmed: 12966604
Sci Transl Med. 2012 Oct 24;4(157):157ra142
pubmed: 23100628
Arthritis Rheumatol. 2015 Apr;67(4):1053-61
pubmed: 25605296
Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7526-E7534
pubmed: 27821747
J Scleroderma Relat Disord. 2017 Sep-Dec;2(3):153-159
pubmed: 29264402
Cancer Cell. 2014 Jan 13;25(1):77-90
pubmed: 24434211
Future Oncol. 2010 Mar;6(3):471-7
pubmed: 20222802
Cancer Epidemiol. 2013 Oct;37(5):523-7
pubmed: 23725641
Arthritis Rheum. 2005 Aug;52(8):2415-24
pubmed: 16052585
Arthritis Res Ther. 2011;13(6):R211
pubmed: 22189167
Biochem Biophys Res Commun. 1987 May 14;144(3):1296-302
pubmed: 3579959
J Urol. 2015 Apr;193(4):1163-9
pubmed: 25463993
Clin Rheumatol. 2016 Jun;35(6):1529-33
pubmed: 27118199
J Dermatol. 2015 May;42(5):524-7
pubmed: 25720827